Developing an expert panel process to refine health outcome definitions in observational data

Journal of Biomedical Informatics

Volumn 46, Issue 5, 2013, Pages 795-804

  Fox, Brent I ^a   Hollingsworth, Joshua C ^a   Gray, Michael D ^b   Hollingsworth, Michael L ^c   Gao, Juan ^a   Hansen, Richard A ^a  

^a AUBURN UNIVERSITY   (United States)

^b HEWLETT PACKARD LABORATORIES   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

Administrative claims; Dashboard; Expert panel; Health outcome of interest; Observational

Indexed keywords

ADMINISTRATIVE CLAIMS; DASHBOARD; EXPERT PANELS; HEALTH OUTCOMES; OBSERVATIONAL;

BIOLOGICAL ORGANS; DIGITAL DEVICES; HEALTH; HOSPITAL DATA PROCESSING; WEBSITES;

ITERATIVE METHODS;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ARTICLE; COMPUTER SECURITY; CONSENSUS DEVELOPMENT; DATA BASE; DELPHI STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMATION PROCESSING; LIVER INJURY; OBSERVATIONAL STUDY; PATIENT CODING; PRIORITY JOURNAL;

ADMINISTRATIVE CLAIMS; DASHBOARD; EXPERT PANEL; HEALTH OUTCOME OF INTEREST; OBSERVATIONAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMPUTER SECURITY; HUMANS; INTERNET; MEDICAL AUDIT; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84883793103     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2013.05.006     Document Type: Article

References (27)

1. Ernst F.R., Grizzle A.J. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc 2001, 41:192-199.
2. Goettler M., Schneeweiss S., Hasford J. Adverse drug reaction monitoring-cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997, 6(Suppl. 3):S79-S90.
3. Kane-Gill S.L., Van Den Bos J., Handler S.M. Adverse drug reactions in hospital and ambulatory care settings identified using a large administrative database. Ann Pharmacother 2010, 44:983-993.
4. Moore N., Lecointre D., Noblet C., Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998, 45:301-308.
5. Muehlberger N., Schneeweiss S., Hasford J. Adverse drug reaction monitoring-cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997, 6(Suppl. 3):S71-S77.
6. Patel H., Bell D., Molokhia M., Srishanmuganathan J., Patel M., Car J., et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol 2007, 7:9.
7. Patel K.J., Kedia M.S., Bajpai D., Mehta S.S., Kshirsagar N.A., Gogtay N.J. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007, 7:8.
8. Committee on the Assessment of the US Drug Safety System. In: Baciu A, Stratton K, Burke SP, editors. The future of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies; 2007.
9. Food and Drug Admininstration Amendments Act of 2007, Pub. L. No. 110-85, § 905.
10. Food and Drug Administration. The Sentinel Initiative: national strategy for monitoring medical product safety; 2012. <> (accessed 01.06.12). http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM124701.pdf.
11. Behrman R.E., Benner J.S., Brown J.S., McClellan M., Woodcock J., Platt R. Developing the sentinel system - a national resource for evidence development. New Engl J Med 2011, 364:498-499.
12. Stang P.E., Ryan P.B., Racoosin J.A., Overhage J.M., Hartzema A.G., Reich C., et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010, 153:600-606.
13. President's Council of Advisors on Science and Technology. Realizing the full potential of health information technology to improve healthcare for Americans: the path forward; 2012. < (accessed 01.06.12). http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-health-it-report.pdf.
14. Strom B.L. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001, 10:389-392.
15. Stang P.E., Ryan P.B., Dusetzina S.B., Hartzema A.G., Reich C., Overhage J.M., et al. Health Outcomes of interest in observational data: issues in identifying definitions in the literature. Health Outcomes Res Med 2012, 3:e37-e44.
16. Observational Medical Outcomes Partnership. Health outcomes of interest library; 2011. <> (accessed June 2011). http://omop.fnih.org/HOI.
17. Overhage J.M., Ryan P.B., Reich C.G., Hartzema A.G., Stang P.E. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012, 19:54-60.
18. Observational Medical Outcomes Partnership. OSCAR - Observational source characteristics analysis report design and specification and feasibility assessment; 2011. <> (accessed June 2011). http://omop.fnih.org/OSCAR.
19. Observational Medical Outcomes Partnership. NATHAN - Utility of natural history information; 2011. <> (accessed June 2011). http://omop.fnih.org/NATHAN.
20. Regenstrief Institute. Logical Observation Identifiers Names and Codes (LOINC); 2011. <> (accessed June 2011). http://www.loinc.org.
21. Bennett C.L., Nebeker J.R., Yarnold P.R., Tigue C.C., Dorr D.A., McKoy J.M., et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the food and drug administration and pharmaceutical manufacturers. Arch Intern Med 2007, 167:1041-1049.
22. Fraunfelder F.W., Fraunfelder F.T. Adverse ocular drug reactions recently identified by the national registry of drug-induced ocular side effects. Ophthalmology 2004, 111:1275-1279.
23. Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372.
24. Mini-Sentinel. Validation of health outcomes; 2011. <> (accessed 25.01.13). http://mini-sentinel.org/methods/outcome_validation/default.aspx.
25. Mini-Sentinel. Identification of health outcomes; 2011. <> (accessed 25.01.13). http://mini-sentinel.org/methods/outcome_identification/default.aspx.
26. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub E., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007, 45:S89-S95. 10.1097/MLR.0b013e3180616c0a.
27. Brownstein J.S., Murphy S.N., Goldfine A.B., Grant R.W., Sordo M., Gainer V., et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010, 33:526-531.